NCT03548584View on ClinicalTrials.gov

A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type

PHASE3CompletedINTERVENTIONAL

Enrollment

345

Participants

Timeline

Start Date

May 16, 2018

Primary Completion Date

May 23, 2022

Study Completion Date

June 1, 2022

Conditions

Agitation Associated With Alzheimer's DementiaAlzheimer Dementia

Interventions

DRUG

Brexpiprazole

Oral tablets

OTHER

Placebo

Oral tablets

Trial Locations (1)

90036

For additional information regarding sites, contact 844-687-8522, Los Angeles

All Listed Sponsors

collaborator

H. Lundbeck A/S

INDUSTRY

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT03548584 - A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type | Biotech Hunter | Biotech Hunter